## E UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Akerman et al.

Serial No.:

10/591,214

Group Art Unit No.: Not Yet Assigned

Filed:

August 28, 2006

Examiner:

Not Yet Assigned

For:

COMPOUNDS, PHARMACEUTICAL

COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS

Docket No.:

A-988A

## INFORMATION DISCLOSURE STATEMENT

### **Mail Stop Amendment**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicants submit a "List of References" Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references that is not a U.S. Patent or Published U.S. Patent Application for consideration by the Examiner.

Applicants make no determination of relevancy with respect to the references submitted herewith and request the Examiner to make an independent determination of relevance and/or materiality of the references.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Identification of the listed references is not to be construed as an Admission by Applicants or attorney for Applicants that such references are available or qualify as "prior art" against the subject application. Applicants reserve the right to remove any such reference which the Patent and Trademark Office may cite against the subject application.

Applicants request consideration of this information and passage of the application to issue.

#### **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Priority mail in a box addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

Applicants believe that no fee is due for the filing of this Information Disclosure Statement. However, in the event any fee is due the Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Date: February 9, 2007

Bernard P. Friedrichsen

Attorney/Agent for Applicant(s)

Registration No.: 44,689 Phone: (805) 447-0628

Please send all future correspondence to:

US Patent Operations/BPF Dept. 4300; M/S 28-2-C AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799

	1			Sheet	1	of	<u>3</u>
	Modified Form PTO-1449	Atty. Docket No.		Serial No.			
			A-988A		10/5	91,214	
6	LIST OF REFERENCES CITED BY APPL	ICANT Applicant					
	<b>&gt;</b>		Akerman et al.				
FER	(Use several sheets if necessary)	Filing Date		Group			
7 -	£)		August 28, 2006	l	Inassi	gned	
AR.	TRADEMART					-	
100	TRADEAN U.S.	. PATENT DOCUMENTS	3				

# **U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

### **FOREIGN PATENT DOCUMENTS**

 · · ·	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-	TRANS	LATION
					CLASS	YES	NO
D1	WO 04/092117 A1	28 Oct 2004	PCT				
D2	WO 05/051890 A1	9 Jun 2005	PCT				
D3	WO 05/058848 A1	30 Jun 2005	PCT			-	
 D4	WO 05/063725 A1	14 Jul 2005	PCT (English Abstract included)			-	х
D5	WO 05/063729 A1	14 Jul 2005	PCT				
D6	WO 05/087710 A1	22 Sep 2005	PCT (English Abstract included)				х
D7	WO 06/001092 A1	5 Jan 2006	PCT (English Abstract included)				х
D8	WO 06/011615 A1	2 Feb 2006	PCT (English Abstract included)				х
 D9	WO 06/083612 A1	10 Aug 2006	PCT				
D10	WO 06/083781 A1	10 Aug 2006	PCT				

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

C1	Bachmann, et al., "The Synthesis of an Analog of the Sex Hormones", <i>Jnl. Amer. Chem. Soc.</i> , <u>64</u> : 94-97 (1942).
C2	Berthelot, et al., "Synthesis and Pharmacological Evaluation of γ-Aminobutyric Acid Analogues. New Ligand for GABA <sub>B</sub> Sites", <i>Jnl. Med. Chem.</i> , 30: 743-746 (1987).
C3	Boyle, et al., "Applications of the spiroannulation of tetralins with alkynes; towards new antiestrogenic compounds", <i>Jnl. Chem. Soc., Perkin Trans. Org. and Bioorg. Chem.</i> , <u>18</u> : 2707-2711 (1997).
C4	Briscoe, et al., "The Orphan G Protein-Coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids", <i>Jnl. of Biol. Chem.</i> , <u>278</u> : 11303-11311 (2003).
C5	Briscoe, et al., "Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules", <i>Brit. Jnl. of Pharm.</i> , 148: 619-628 (2006).
C6	Burnop, et al., "Fused Carbon Rings. Part XIX. Experiments on the Synthesis of Tetracyclic Compounds of the Sexual Hormonal Type", <i>Jnl. Chem. Soc.</i> , 727-735 (1940).
C7	Chatterjee, et al., "Studies on Nucleophilic Ring Opening of Some Epoxides in Polar Protic Solvents", <i>Tetr.</i> , 33: 85-94 (1977).
C8	Collins, et al., "The Structure and Function of Oestrogens. IX. Synthesis of the <i>trans</i> Isomer of 5,5,10b-Trimethyl-4b,5,6,10b,11,12-hexahydrochrysene-2,8-diol", <i>Aust. Jnl. Chem.</i> , 41: 735-744 (1988).

EXAMINER:	Date Considered:
·	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if no communication to applicant.	ot in conformance and not considered. Include copy of this form with next

		Sheet	2	<u>of</u>	3
Atty. Docket No.		Serial No.			
	A-988A		10/5	91,214	
Applicant	<u> </u>				
	Akerman et al.				
Filing Date		Group			

Modified Form PTO-1449 CAST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) August 28, 2006 Unassigned

<u> </u>	<u>.~/</u>	
ارمير	<i>\$</i>	
Vra TAMPAZE	C9	Deb, et al., "A Stereocontrolled Synthesis of (1'RS,2'SR)-3-Oxo-3',4'-dihydrospiro[ cyclopentane-1,1'(2'H)-naphthalen]- 2 - ylacetic Acid and its Methoxy Analogues", <i>Jnl. Chem. Res. S.</i> , 12: 406 (1985).
	C10	DeWolf, et al., "Inactivation of Dopamine β-Hydroxylase by β-Ethynyltyramine: Kinetic Characterization and Covalent Modification of an Active Site Peptide", <i>Biochem.</i> , <u>28</u> : 3833-3842 (1989).
	C11	Egan, et al., "Naphthalenes as inhibitors of myeloperoxidase: Direct and indirect mechanisms of inhibition", <i>Agents and Actions</i> , 29 3/4, 266-276 (1990).
	C12	Frey, et al., "Total Synthesis of Pentacyclic Diterpenoid Tropone Hainanolidol," Aust. Jnl. Chem., 53: 819-830 (2000).
	C13	Galemmo, et al., "The Development of a Novel Series of (Quinolin-2-ylmethoxy) phenyl-Containing Compounds as High-Affinity Leukotriene Receptor Antagonists. 3. Structural Variation of the Acidic Side Chain To Give Antagonists of Enhanced Potency", <i>Jnl. Med. Chem.</i> , 33: 2828-2841 (1990).
	C14	Garrido, et al., "Synthesis and activity of small molecule GPR40 agonists," <i>Bioorg. and Med. Chem. Lett.</i> , 16: 1840-1845 (2006).
	C15	Ghosal, et al., "Stereospecific Synthesis of 9bβ-Carbomethoxy-7-Methoxy-2,3,3aα,4,5,9bβ-Hexahydro-1H-Benz[e]Inden-2-one; An Intermediate Towards Physiologically Active Compounds," <i>Tet. Lett.</i> , <u>17</u> : 1463-1464 (1977).
	C16	Guthrie, et al., "Synthesis in the Series of Diterpene Alkaloids VI. A Simple Synthesis of Atisine," <i>Tet. Lett.</i> , 38: 4645-4654 (1966).
	C17	Haigh, et al., "Non-thiazolidinedione Antihyperglycaemic Agents. Part 3: The Effects of Stereochemistry on the Potency of α-Methoxy-β-phenylpropanoic Acids," <i>Bioorg. &amp; Med. Chem.</i> , $\underline{7}$ : 821-830 (1999).
	C18	Hares, et al., "Synthetic Studies of Tricyclospirodienones; Model Chemistry for Novel Mimics of Steroid Substrates", <i>Jnl. Chem. Soc. Perkin Trans. I: Org. and Bioorg. Chem.</i> , <u>13</u> 1481-1492 (1993).
	C19	lizuka, et al., "β-Substituted Phenethylamines as High Affinity Mechanism-Based Inhibitors of Dopamine β-Hydroxylase", <i>Jnl. Med. Chem.</i> , 31: 704-706 (1988).
	C20	!shikawa, et al., "Actions of the novel oral antidiabetic agent HQL-975 in insulin-resistant non-insulin –dependent diabetes mellitus model animals", <i>Diabetes Rsh. and Clin. Pract.</i> , 41: 101-111 (1998).
	C21	Ishikawa, et al., "Effects of the novel oral antidiabetic agent HQL-975 on Glucose and Lipid Metabolism in Diabetic db/db Mice," <i>Arzneim. Forsch. Drug Rsh.</i> , 48 (I): 245-250 (1998).
	C22	Itoh, et al., "Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40," <i>Nature</i> , 422: 173-176 (2003).
	C23	Johns, et al., "Total Synthesis of Estrajervatetraene," Jnl. Org. Chem., 44: 958-961 (1979).
	C24	Kolasa, et al., "Symmetrical Bis(heteroarylmethoxyphenyl)alkylcarboxylic Acids as Inhibitors of Leukotriene Biosynthesis," <i>Jnl. Med. Chem.</i> , 43: 3322-3334 (2000).
	C25	Kotarsky, et al., "A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs", <i>Biochem. and Biophys. Rsh. Comm.</i> , 301: 406-410 (2003).
,	C26	Kuchar, et al., "Benzyloxyarylaliphatic Acids: Synthesis and Quantitative Relations Between Structure and Antiinflammatory Activity", <i>Collection Czech. Chem., Commun.</i> , <u>47</u> : 2514-2524 (1982).

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if n	ot in conformance and not considered. Include copy of this form with next

Sheet	3	of	
Olleet	J	- 01	

		Sheet 3 of 3
Modified Form PTO-1449	Atty. Docket No.	Serial No.
	A-988A	10/591,214
EST OF REFERENCES CITED BY APPLICANT	Applicant	
	Akerman et al.	
(Use several sheets if necessary)	Filing Date	Group
<b>8</b> (111111111111111111111111111111111111	August 28, 200	06 Unassigned

<u> </u>	R.L	
.45	<b>7</b>	
ENT & TRAM	01.	Kuchar, et al., "The Effects of Lopophilicity on the Inhibition of Denaturation of Serum Albumin and on the Activation of Fibrinolysis Observed with a Series of Benzyloxyarylaliphatic Acids", <i>Collection Czech. Chem, Commun.</i> , 48: 1077-1088 (1983).
	C28	Lin, et al., "The Discovery of Acylated β-Amino Acids as Potent and Orally Bioavailable VLA-4 Antagonists," <i>Bioorg. &amp; Med. Chem. Lett.,</i> <u>12</u> : 611-614 (2002).
	C29	Liu, et al., "Synthesis and Biological Activity of L-Tyrosine-based PPARγ Agonists with Reduced Molecular Weight", <i>Bioorg. &amp; Med. Chem. Lett.</i> , <u>11</u> : 3111-3113 (2001).
	C30	Nilsson, et al., "Identification of a free fatty acid receptor, FFA <sub>2</sub> R, expressed on leukocytes and activated by short-chain fatty acids, " <i>Biochem. and Biophys. Rsh. Commun.</i> , 303 1047-1052 (2003).
	C31	Oliver, et al., "A selective peroxisome proliferator-activated receptor $\delta$ agonist promotes reverse cholesterol transport", <i>PNAS</i> , <u>98</u> : 5306-5311 (2001).
	C32	Poitout, V., "The ins and outs of fatty acids on the pancreatic β cell", <i>Trends in Endocrin.</i> and Metab., 14: 201-203 (2003).
	C33	Ray, et al., "Synthesis of Some Angularly Cyclopentanone Fused Hydrophenanthrene and Hydrofluorene Derivatives by Acid-Catalyzed Intramolecular C-Alkylation of $\gamma$ , $\delta$ - Unsaturated $\alpha$ '-Diazomethyl Ketones", <i>Synth. Commun.</i> , <u>21</u> : 1223-1242 (1991).
	C34	Sandberg, et al., "N-Aminoalkylsuccinimides as local anaesthetics", <i>Acta Pharmaceutica Suecica</i> , 17: 169-176 (1980).
	C35	Sanyal, et al., "A Novel Synthesis of a Tricyclo (7.5.0 <sup>1,5</sup> .0 <sup>1,9</sup> ) Tetradecane Ring System Related to Gascardic Acid," <i>Tet. Lett.</i> , <u>25</u> : 2187-2190 (1978).
	C36	Sarma, et al., "Synthetic Studies on Terpenoids. Parts XVIII. <sup>1,2</sup> Stereocontrolled Synthesis of (±)-1,2,3,4,4a,9,10,10aα-Octahydro-1α-methylphenanthrene-1β,4aβ-dicarboxylic acid and the 7-Methoxy Analogue: A Potential Intermediate for Diterpenoid Syntheses", <i>Jnl. Chem. Soc. Perkin Trans. I: Organic and Bioorg. Chem.</i> , 7: 722-727 (1976).
	C37	Sawzdargo, et al., "A Cluster of Four Novel Human G Protein-Coupled Receptor Genes Occurring in Close Proximity to CD22 Gene on Chromosome 19q13.1", <i>Biochem. and Biophys. Rsh. Commun.</i> , 239: 543-547 (1997).
	C38	Shaw, et al., "Enantioselective Synthesis of (+)-(2S,3S)-3-Ethynyltyrosine", <i>Tet. Lett.</i> , <u>31</u> : 5081-5084 (1990).
	C39	Shiotani, et al., "Synthesis of 1,3-Bridged 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine Derivatives <sup>1</sup> " Chem. Pharm. Bull., <u>28</u> : 1928-1931 (1980).
	C40	Waid, et al., "Constrained Amino Acids. An Approach to the Synthesis of 3-Substituted Prolines," <i>Tet. Lett.</i> , <u>37</u> : 4091-4094 (1996).

EXAMINER:	Date Considered: